Barclays PLC Amylyx Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 84,572 shares of AMLX stock, worth $338,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,572

Previous 84,572 -0.0%

Holding current value

$338,288

Previous $274,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.65 - $3.24 $66,526 - $130,633	40,319 Added 91.11%	84,572 $274,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $101,394 - $169,616	-62,589 Reduced 58.58%	44,253 $84,000
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $43,259 - $312,395	15,963 Added 17.57%	106,842 $304,000
Q4 2023 Feb 15, 2024	BUY	$12.07 - $18.46 $786,722 - $1.2 Million	65,180 Added 253.63%	90,879 $1.34 Million
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $945,312 - $1.23 Million	-52,285 Reduced 67.05%	25,699 $470,000
Q2 2023 Aug 03, 2023	SELL	$20.98 - $31.42 $82,283 - $123,229	-3,922 Reduced 4.79%	77,984 $1.68 Million
Q1 2023 May 04, 2023	BUY	$27.71 - $40.93 $1.2 Million - $1.78 Million	43,411 Added 112.77%	81,906 $2.4 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $585,926 - $773,225	19,695 Added 104.76%	38,495 $1.42 Million
Q3 2022 Nov 03, 2022	BUY	$17.15 - $30.92 $312,558 - $563,517	18,225 Added 3169.57%	18,800 $529,000
Q2 2022 Aug 12, 2022	SELL	$6.85 - $19.93 $6,740 - $19,611	-984 Reduced 63.12%	575 $11,000
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $20,033 - $51,291	1,559 New	1,559 $20,000

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $234M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account